TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling

Nature Cell Biology

Volumn 15, Issue 11, 2013, Pages 1351-1361

  Bragado, Paloma ^a   Estrada, Yeriel ^a   Parikh, Falguni ^a   Krause, Sarah ^b   Capobianco, Carla ^c   Farina, Hernan G ^c   Schewe, Denis M ^a,b   Aguirre Ghiso, Julio A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN P27; SMAD1 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW METASTASIS; CELL FATE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; HEAD AND NECK SQUAMOUS CELL CARCINOMA; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANIMALS; CELL LINEAGE; ENZYME ACTIVATION; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA2; TUMOR MICROENVIRONMENT;

EID: 84887219089     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb2861     Document Type: Article

References (53)

1. Fidler, I. J. The pathogenesis of cancer metastasis: the ̀seed and soil' hypothesis revisited. Nat. Rev. Cancer 3, 453-458 (2003). (Pubitemid 37328849)
2. Aguirre-Ghiso, J. A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834-846 (2007). (Pubitemid 350006258)
3. Klein, C. A. Framework models of tumor dormancy from patient-derived observations. Curr. Opin. Genet. Dev. 21, 42-49 (2011).
4. Ferlito, A., Shaha, A. R., Silver, C. E., Rinaldo, A. & Mondin, V. Incidence and sites of distant metastases from head and neck cancer. ORL J. Otorhinolaryngol. Relat. Spec. 63, 202-207 (2001). (Pubitemid 32620169)
5. Zhang, Y., Ma, B. & Fan, Q. Mechanisms of breast cancer bone metastasis. Cancer Lett. 292, 1-7 (2010).
6. Husemann, Y. & Klein, C. A. The analysis of metastasis in transgenic mouse models. Transgenic Res. 18, 1-5 (2009).
7. Husemann, Y. et al. Systemic spread is an early step in breast cancer. Cancer Cell 13, 58-68 (2008). (Pubitemid 350309740)
8. Adam, A. P. et al. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Res. 69, 5664-5672 (2009).
9. Kim, R. S. et al. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS One 7, e35569 (2012).
10. Onder, T. T. et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 483, 598-602 (2012).
11. Montagner, M. et al. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 487, 380-384 (2012).
12. Bao, B. et al. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J. Cell Biochem. 112, 2296-2306 (2011).
13. Sorrentino, A. et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol. 10, 1199-1207 (2008).
14. Ito, K. et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat. Med. 12, 446-451 (2006).
15. Zijlstra, A. et al. A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res. 62, 7083-7092 (2002). (Pubitemid 35424104)
16. Riethdorf, S., Wikman, H. & Pantel, K. Review: biological relevance of disseminated tumor cells in cancer patients. Int. J. Cancer 123, 1991-2006 (2008).
17. Toolan, H. W. Transplantable human neoplasms maintained in cortisonetreated laboratory animals: H.S. #1; H.Ep. #1; H.Ep. #2; H.Ep. #3; and H.Emb.Rh. #1. Cancer Res. 14, 660-666 (1954).
18. Ossowski, L. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell 52, 321-328 (1988). (Pubitemid 18057393)
19. Aguirre-Ghiso, J. A., Liu, D., Mignatti, A., Kovalski, K. & Ossowski, L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 12, 863-879 (2001). (Pubitemid 33051984)
20. Ossowski, L. & Reich, E. Experimental model for quantitative study of metastasis. Cancer Res. 40, 2300-2309 (1980). (Pubitemid 10082242)
21. Aguirre-Ghiso, J. A., Ossowski, L. & Rosenbaum, S. K. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res. 64, 7336-7345 (2004). (Pubitemid 39372072)
22. Alonso, D. F. et al. Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma. J. Surg. Oncol. 62, 288-297 (1996). (Pubitemid 26262354)
23. Aslakson, C. J. & Miller, F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399-1405 (1992).
24. Aguirre-Ghiso, J. A., Estrada, Y., Liu, D. & Ossowski, L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 63, 1684-1695 (2003). (Pubitemid 36373662)
25. Kim, J., Yu, W., Kovalski, K. & Ossowski, L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94, 353-362 (1998). (Pubitemid 28376079)
26. Ossowski, L. & Reich, E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35, 611-619 (1983). (Pubitemid 14168365)
27. Henckaerts, E., Langer, J. C., Orenstein, J. & Snoeck, H-W. The positive regulatory effect of TGF-β2 on primitive murine hemopoietic stem and progenitor cells is dependent on age, genetic background, and serum factors. J. Immunol. 173, 2486-2493 (2004). (Pubitemid 39063106)
28. Gao, H. et al. The BMP inhibitor coco reactivates breast cancer cells at lung metastatic sites. Cell 150, 764-779 (2012).
29. Lopez-Casillas, F., Wrana, J. L. & Massague, J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell 73, 1435-1444 (1993). (Pubitemid 23201155)
30. Criswell, T. L., Dumont, N., Barnett, J. V. & Arteaga, C. L. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Res. 68, 7304-7312 (2008).
31. Siegel, P. M. & Massague, J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer 3, 807-821 (2003).
32. Gath, H. J. & Brakenhoff, R. H. Minimal residual disease in head and neck cancer. Cancer Metastasis Rev. 18, 109-126 (1999). (Pubitemid 29411096)
33. Aguirre-Ghiso, J. A., Bragado, P. & Sosa, M. S. Metastasis awakening: targeting dormant cancer. Nat. Med. 19, 276-277 (2013).
34. Kobayashi, A. et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J. Exp. Med. 208, 2641-2655 (2011).
35. Shiozawa, Y. et al. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12, 116-127 (2010).
36. Padua, D. et al. TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66-77 (2008). (Pubitemid 351442989)
37. Turley, R. S. et al. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res. 67, 1090-1098 (2007).
38. Cheifetz, S. et al. The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 48, 409-415 (1987).
39. Cheifetz, S. et al. Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. J. Biol. Chem. 265, 20533-20538 (1990). (Pubitemid 120014040)
40. Brown, C. B., Boyer, A. S., Runyan, R. B. & Barnett, J. V. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science 283, 2080-2082 (1999).
41. You, H. J., Bruinsma, M. W., How, T., Ostrander, J. H. & Blobe, G. C. The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. Carcinogenesis 28, 2491-2500 (2007). (Pubitemid 350238951)
42. Ajiboye, S., Sissung, T. M., Sharifi, N. & Figg, W. D. More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer. BJU Int. 105, 913-916 (2010).
43. Dong, M. et al. The type III TGF-beta receptor suppresses breast cancer progression. J. Clin. Invest. 117, 206-217 (2007). (Pubitemid 46048467)
44. Sun, C. K., Chua, M. S., He, J. & So, S. K. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-beta2. Neoplasia 13, 735-747 (2011).
45. Yamazaki, S. et al. TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 113, 1250-1256 (2009).
46. Sharifi, N., Hurt, E. M., Kawasaki, B. T. & Farrar, W. L. TGFBR3 loss and consequences in prostate cancer. Prostate 67, 301-311 (2007).
47. Morrissey, C. & Vessella, R. L. The role of tumor microenvironment in prostate cancer bone metastasis. J. Cell Biochem. 101, 873-886 (2007). (Pubitemid 47040869)
48. Ghajar, C. M. et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 15, 807-817 (2013).
49. Ossowski, L., Russo, H., Gartner, M. & Wilson, E. L. Growth of a human carcinoma (HEp3) in nude mice: rapid and efficient metastasis. J. Cell Physiol. 133, 288-296 (1987). (Pubitemid 18000324)
50. Ranganathan, A. C., Zhang, L., Adam, A. P. & Aguirre-Ghiso, J. A. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 66, 1702-1711 (2006). (Pubitemid 43259955)
51. Deryugina, E. I. et al. Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Cancer Res. 65, 10959-10969 (2005). (Pubitemid 41713365)
52. Zijlstra, A., Lewis, J., Degryse, B., Stuhlmann, H. & Quigley, J. P. The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 13, 221-234 (2008). (Pubitemid 351318371)
53. Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253-1270 (2003). (Pubitemid 36583168)